Quotes 5-day view Delayed Nasdaq
01/15/2021
01/19/2021
01/20/2021
01/21/2021
01/22/2021
Date
14.43(c)
15.48(c)
15.08(c)
14.02(c)
15.71(c)
Last
311 906
266 625
350 849
275 901
172 267
Volume
+4.72% +7.28% -2.58% -7.03% +12.05% Change
Sales 2020
-
-
-
Net income 2020
-87,9 M - -
Net cash position 2020
126 M - -
P/E ratio 2020
-6,94x
Yield 2020
-
Sales 2021
-
-
-
Net income 2021
-107 M - -
Net cash position 2021
29,9 M - -
P/E ratio 2021
-7,59x
Yield 2021
-
Capitalization
726 M 726 M -
EV / Sales 2020
-
EV / Sales 2021
-
Nbr of Employees
98
Free-Float
92,8%
Evelo Biosciences, Inc. is engaged in developing therapies designed to act on gut-body network. The Company develops monoclonal microbes that are orally-delivered compositions of specific strains of naturally occurring microbes derived from a single clone. Its principal product candidates include EDP1066, EDP1815, and EDP1503 that are in the pre-clinical development stage. EDP1066 and EDP1815 are monoclonal...
Notations Surperformance© of Evelo Biosciences, Inc.
Trading Rating : Investor Rating : -
All news about EVELO BIOSCIENCES, INC.
News in other languages on EVELO BIOSCIENCES, INC.
- No features available -
Analyst Recommendations on EVELO BIOSCIENCES, INC.
EVELO BIOSCIENCES, INC. - 2020
No turn-around in sight
BUY
Chart EVELO BIOSCIENCES, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends EVELO BIOSCIENCES, INC.
Short Term Mid-Term Long Term Trends Bullish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
5
Average target price
17,50 $
Last Close Price
15,71 $
Spread / Highest target
71,9%
Spread / Average Target
11,4%
Spread / Lowest Target
-30,0%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
